Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Studying the role of soluble ST2 (sST2) during hospitalization for myocardial infarction (MI) can be helpful for predicting the course of the hospitalization and development of complications. Methods: We included 88 patients with MI (median age, 58 yr). Depending on the course of the hospitalization, the patients were divided into two groups: the favorable (n=58) and unfavorable (n=30) outcome groups. On days 1 and 12 after MI, serum sST2 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured by ELISA. Results: On day 1, the concentrations of sST2 and NT-proBNP increased 2.4- and 4.5-fold, compared with the controls. Measurements on day 12 showed a significant decrease in the sST2 level (P=0.001), whereas the NT-proBNP level did not change. On day 1, the sST2 level in the unfavorable outcome group was 2-fold higher than that in the favorable outcome group and 3.7-fold higher than in the controls. On day 12, the marker level decreased in both groups. On day 1, the NT-proBNP level in the unfavorable outcome group was 6.8-fold higher than in the controls and 1.8-fold higher than in the favorable outcome group. On day 12, the level of NT-proBNP remained elevated in both groups. Determining the levels of both sST2 and NT-proBNP increases their diagnostic significance (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.7-3.2; areas under curve [AUC] 0.89; P=0.004). Conclusions: The level of sST2 is a more sensitive indicator during MI hospitalization than NT-proBNP.
Abstract
Background: Studying the role of soluble ST2 (sST2) during hospitalization for myocardial infarction (MI) can be helpful for predicting the course of the hospitalization and development of complications. Methods: We included 88 patients with MI (median age, 58 yr). Depending on the course of the hospitalization, the patients were divided into two groups: the favorable (n=58) and unfavorable (n=30) outcome groups. On days 1 and 12 after MI, serum sST2 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured by ELISA. Results: On day 1, the concentrations of sST2 and NT-proBNP increased 2.4- and 4.5-fold, compared with the controls. Measurements on day 12 showed a significant decrease in the sST2 level (P=0.001), whereas the NT-proBNP level did not change. On day 1, the sST2 level in the unfavorable outcome group was 2-fold higher than that in the favorable outcome group and 3.7-fold higher than in the controls. On day 12, the marker level decreased in both groups. On day 1, the NT-proBNP level in the unfavorable outcome group was 6.8-fold higher than in the controls and 1.8-fold higher than in the favorable outcome group. On day 12, the level of NT-proBNP remained elevated in both groups. Determining the levels of both sST2 and NT-proBNP increases their diagnostic significance (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.7-3.2; areas under curve [AUC] 0.89; P=0.004). Conclusions: The level of sST2 is a more sensitive indicator during MI hospitalization than NT-proBNP.
참고문헌 (25)
- Opie LH, "Controversies in ventricular remodeling", Lancet, 367, pp.356~367 (2006)
- Gravning J, "Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis", Am Heart J, 165, pp.716~724 (2013)
- Ciccone MM, "A novel cardiac bio-marker: ST2: a review", Molecules, 18, pp.15314~15328 (2013)
- Maries L, "Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP)", Cardiovasc J Afr, 7, pp.286~289 (2013)
- Demyanets S, "Components of the interleukin-33", ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature, 2013, pp.60, 16~26
- Chackerian AA, "IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex", J Immunol, 179, pp.2551~2555 (2007)
- Seki K, "Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling", Circ Heart Fail, 2, pp.684~691 (2009)
- Felker GM, "Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes", Circ Heart Fail, 6, pp.1172~1179 (2013)
- Shimpo M, "Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction", Circulation, 109, pp.2186~2190 (2004)
- Kohli P, "Role of ST2 in non–ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial", Clin Chem, 58, pp.257~266 (2012)
- 허미나, "Soluble ST2 Has a Prognostic Role in Patients With Suspected Sepsis", Annals of Laboratory Medicine, 35(6), pp.570~577 (2015), 대한진단검사의학회
- Thygesen K, "Universal definition of myocardial infarction", Circulation, 116, pp.2634~2653 (2007)
- Glanz S, "Primer of biostatistics", pp.496~ (2001), McGraw-Hill Education
- Liang F, "Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes", J Biol Chem, 272, pp.28050~28056 (1997)
- He Q, "Inducible regulation of human brain natriuretic peptide promoter in transgenic mice", Am J Physiol Heart Circ Physiol, 280, pp.H368~H376 (2001)
- Mathewkutty S, "Biomarkers after risk stratification in acute chest pain (from the BRIC Study)", Am J Cardiol, 111, pp.493~498 (2013)
- Kakkar R, "The IL-33", ST2 pathway: therapeutic target and novel biomarker, 2008, pp.7, 827~840
- Sabatine MS, "Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction", Circulation, 117, pp.1936~1944 (2008)
- Miller AM, "Role of IL-33 in inflammation and disease", J Inflamm, 8, pp.22~ (2011)
- Sanada S, "IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system", J Clin Invest, 117, pp.1538~1549 (2007)
- Januzzi JL, "ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel", Am J Cardiol, 115(S7), pp.26B~31B (2015)
- Mueller T, "Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases", Clin Chim Acta, 445, pp.155~160 (2015)
- Gruzdeva O, "Lipid, adipokine and ghrelin levels in myocardial infarction patients with insulin resistance", BMC Cardiovasc Disord, 14, pp.7~ (2014)
- Weinberg EO, "Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction", Circulation, 106, pp.2961~2966 (2002)
- Demyanets S, "Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome", PLoS One, 9, pp.e95055~ (2014)